Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
2개의 RNA 기반 Covid-19 백신 후보의 안전성 및 면역원성
Clinical Trial
[키워드] acute respiratory syndrome
added
Adults
age
assigned
BNT162b1
BNT162b2
candidate
conducted
convalescent serum
coronavirus
coronavirus disease
defined
disease
dose
dose-dependent
dose-escalation
doses
Efficacy
elicited
ENCODE
full-length
geometric mean titer
geometric mean titers
Germany
group
healthy
immunogenicity
immunogenicity data
incidence
Infection
Interim
Local
Multiple
nucleoside-modified RNA
observer-blinded
of BNT162b2
Older
participant
Participants
phase 1 trial
Placebo
placebo-controlled
prefusion conformation
Primary outcome
randomization
Randomly
receive
reported
resulting
Safety
SARS-CoV-2
secondary outcome
secreted
severity
spread to
Support
systemic reaction
The United States
the vaccine
Trial
Vaccine
vaccine candidate
vaccine dose
[DOI] 10.1056/NEJMoa2027906 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2027906 PMC 바로가기 [Article Type] Clinical Trial